The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Open accessAbstract
BACKGROUND & AIMS: We analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and ACT-2) to assess relationships between serum concentrations of infliximab and outcomes of adults with moderate-to-severe ulcerative colitis. METHODS: We compared serum concentrations of infliximab with outcomes of 728 patients with moderately-to-severely active ulcerative colitis who participated in ACT-1 or ACT-2; efficacy data were collected at weeks 8, 30, and 54 (for ACT-1 only). Relationships between serum concentration of infliximab and efficacy outcomes were assessed using trend, logistic regression, and receiver operating characteristic curve analyses. We also evaluated factors that affected the relationship between exposure and response. RESULTS: Median serum concentrations of infliximab at weeks 8, 30, and/or 54 were significantly higher in patients with clinical response, mucosal healing, and/or clinical remission than in patients who did not meet these response criteria. There were statistically significant relationships between quartile of infliximab serum concentration and efficacy at these time points (P < .01). Infliximab therapy was effective for a smaller proportion of patients in the lowest quartile, and these patients had lower serum levels of albumin and a higher incidence of antibodies to infliximab than patients in other quartiles. Although the relationship between exposure to infliximab and response varied among patients, approximate serum concentrations of 41 μg/mL infliximab at week 8 of induction therapy and 3.7 μg/mL at steady-state during maintenance therapy produced optimal outcomes in patients. CONCLUSIONS: Serum concentrations of infliximab are associated with efficacy in patients with moderate-to-severe ulcerative colitis; however, complex factors determine the relationship between exposure to this drug and response. A prospective evaluation of the value of measuring serum concentrations of infliximab should be performed before these data can be included in patient management strategies. Clinicaltrials.gov numbers: NCT00036439 and NCT00096655.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Self-citationSandborn, W. J., Feagan, B. G., Marano, C., Zhang, H., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Colombel, J., Reinisch, W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.06.010 · Cited by 727
Self-citationHanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
Self-citationMaser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Seow, C. H., Newman, A., Irwin, S. P., Steinhart, A. H., Silverberg, M. S., & Greenberg, G. R. (2010) · Gut · doi:10.1136/gut.2009.183095 · Cited by 536
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
Self-citationAfif, W., Loftus, E. V., Faubion, W. A., Kane, S. V., Bruining, D. H., Hanson, K. A., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.9 · Cited by 486
Self-citationKarmiris, K., Paintaud, G., Noman, M., Magdelaine–Beuzelin, C., Ferrante, M., Degenne, D., Claes, K., Coopman, T., Van Schuerbeek, N., Van Assche, G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.062 · Cited by 478
Self-citationSteenholdt, C., Brynskov, J., Thomsen, O. Ø., Munck, L. K., Fallingborg, J., Christensen, L. A., Pedersen, G., Kjeldsen, J., Jacobsen, B. A., Oxholm, A. S., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305279 · Cited by 460
St.Clair, E. W., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A., & Keystone, E. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10302 · Cited by 417
Cornillie, F., Hanauer, S. B., Diamond, R. H., Wang, J., Tang, K. L., Xu, Z., Rutgeerts, P., & Vermeire, S. (2014) · Gut · doi:10.1136/gutjnl-2012-304094 · Cited by 374
Self-citationAntibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Vande Casteele, N., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P., & Vermeire, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.12 · Cited by 346
Self-citationPopulation pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Fasanmade, A. A., Adedokun, O. J., Ford, J., Hernandez, D., Johanns, J., Hu, C., Davis, H. M., & Zhou, H. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0718-4 · Cited by 327
Self-citationFasanmade, A. A., Adedokun, O. J., Olson, A., Strauss, R., & Davis, H. M. (2010) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp48297 · Cited by 245
Self-citationBortlik, M., Duricova, D., Malickova, K., Machkova, N., Bouzkova, E., Hrdlicka, L., Komarek, A., & Lukas, M. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.10.019 · Cited by 232
Paul, S., Del Tedesco, E., Marotte, H., Rinaudo-Gaujous, M., Moreau, A., Phelip, J.-M., Genin, C., Peyrin-Biroulet, L., & Roblin, X. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182a77b41 · Cited by 222
Steenholdt, C., Bendtzen, K., Brynskov, J., Thomsen, O. Ø., & Ainsworth, M. A. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2010.536254 · Cited by 175
Gottlieb, A. B., Masuda, S., Ramamurthi, R., Abdulghani, A. A., Romano, P., Chaudhari, U., Dooley, L. T., Fasanmade, A. A., & Wagner, C. L. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.10 · Cited by 166
Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease
Cassinotti, A., & Travis, S. P. L. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20899 · Cited by 130
Siddiqui, M. A. A., & Scott, L. J. (2005) · Drugs · doi:10.2165/00003495-200565150-00014 · Cited by 83
Mulleman, D., Lin, D. C. M., Ducourau, É., Emond, P., Ternant, D., Magdelaine–Beuzelin, C., Valat, J., Paintaud, G., & Goupille, P. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181cc6fef · Cited by 67
(1950) · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
Cited by
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J.-F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32126-2 · Cited by 3,531
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Kobayashi, T., Siegmund, B., Le Berre, C., Wei, S. C., Ferrante, M., Shen, B., Bernstein, C. N., Danese, S., Peyrin-Biroulet, L., & Hibi, T. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0205-x · Cited by 1,649
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., Bachmann, O., Bettenworth, D., Chaparro, M., Czuber-Dochan, W., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab178 · Cited by 1,100
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Self-citation
Metadata
- Authors
- Adedokun, O. J., Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Xu, Z., Marano, C. W., Johanns, J., Zhou, H., Davis, H. M., Cornillie, F., & Reinisch, W.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 147
- Issue
- 6
- Pages
- 1296-1307.e5
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2099169909
- Cited by
- 341
- References
- 24
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.